Renal colic

Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the Upcoming American Urological Association Conference (AUA) in September 2021

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Anatomy, Urinary bladder disorders, Urology, Interstitial cystitis, Trigone, Urinary bladder, Overactive bladder, Renal colic

IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.

Key Points: 
  • IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.
  • Our preliminary results should be further confirmed in the upcoming Phase IIa trial, said Dan Touitou, Chief Executive Officer of Trigone Pharma.
  • The data has also prompted us to evaluate the safety and efficacy in overactive bladder and renal colic patients.
  • Trigone Pharma is aiming to restore the quality of life for patients suffering from bladder diseases that affect populations with unmet medical needs.